230 related articles for article (PubMed ID: 22504044)
21. FC gamma receptor polymorphisms in patients with immune thrombocytopenia.
Pavkovic M; Petlichkovski A; Karanfilski O; Cevreska L; Stojanovic A
Hematology; 2018 Apr; 23(3):163-168. PubMed ID: 28942727
[TBL] [Abstract][Full Text] [Related]
22. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility.
Kyogoku C; Dijstelbloem HM; Tsuchiya N; Hatta Y; Kato H; Yamaguchi A; Fukazawa T; Jansen MD; Hashimoto H; van de Winkel JG; Kallenberg CG; Tokunaga K
Arthritis Rheum; 2002 May; 46(5):1242-54. PubMed ID: 12115230
[TBL] [Abstract][Full Text] [Related]
23. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population.
Sadki K; Lamsyah H; Rueda B; Akil E; Sadak A; Martin J; El Aouad R
J Genet Genomics; 2010 Apr; 37(4):257-64. PubMed ID: 20439102
[TBL] [Abstract][Full Text] [Related]
24. Effect of Fc-γ Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation.
Sakai H; Tanaka Y; Tazawa H; Shimizu S; Verma S; Ohira M; Tahara H; Ide K; Ishiyama K; Kobayashi T; Onoe T; Ohdan H
Transplant Direct; 2017 Jun; 3(6):e164. PubMed ID: 28620648
[TBL] [Abstract][Full Text] [Related]
25. Effect of FCGR2A and FCGR3A variants on CLL outcome.
Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
[TBL] [Abstract][Full Text] [Related]
26. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
[TBL] [Abstract][Full Text] [Related]
27. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
[TBL] [Abstract][Full Text] [Related]
28. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
29. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
30. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
Lin TS; Flinn IW; Modali R; Lehman TA; Webb J; Waymer S; Moran ME; Lucas MS; Farag SS; Byrd JC
Blood; 2005 Jan; 105(1):289-91. PubMed ID: 15217834
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
32. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
[TBL] [Abstract][Full Text] [Related]
33. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
34. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes T; Melchardt T; Hufnagl C; Weiss L; Mittermair C; Neureiter D; Klieser E; Rinnerthaler G; Roesch S; Gaggl A; Greil R; Egle A
Pharmacogenomics J; 2018 May; 18(3):474-479. PubMed ID: 28719596
[TBL] [Abstract][Full Text] [Related]
35. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms.
Manger K; Repp R; Jansen M; Geisselbrecht M; Wassmuth R; Westerdaal NA; Pfahlberg A; Manger B; Kalden JR; van de Winkel JG
Ann Rheum Dis; 2002 Sep; 61(9):786-92. PubMed ID: 12176802
[TBL] [Abstract][Full Text] [Related]
36. FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.
Wang B; Kokhaei P; Mellstedt H; Liljefors M
Int J Oncol; 2010 Dec; 37(6):1599-606. PubMed ID: 21042730
[TBL] [Abstract][Full Text] [Related]
37. Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab.
Shimizu C; Mogushi K; Morioka MS; Yamamoto H; Tamura K; Fujiwara Y; Tanaka H
Breast Cancer; 2016 Jul; 23(4):624-32. PubMed ID: 25962696
[TBL] [Abstract][Full Text] [Related]
38. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
39. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
[TBL] [Abstract][Full Text] [Related]
40. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC; Nowicka M; Hargreaves CE; Burton C; Davies A; Ganderton R; Hiddemann W; Iriyama C; Klapper W; Latham KV; Martelli M; Mir F; Parker H; Potter KN; Rose-Zerilli MJJ; Sehn LH; Trněný M; Vitolo U; Bolen CR; Klein C; Knapp A; Oestergaard MZ; Cragg MS
Blood Adv; 2021 Aug; 5(15):2935-2944. PubMed ID: 34323957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
